Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities (2017 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $76.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 1.87% to $76.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.2 million, a 1.87% decrease, with the full-year FY2025 number at $76.2 million, down 1.87% from a year prior.
  • Total Non-Current Liabilities was $76.2 million for Q4 2025 at Iovance Biotherapeutics, down from $76.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $106.6 million in Q1 2024 to a low of $70.6 million in Q1 2023.
  • A 3-year average of $82.7 million and a median of $78.7 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 50.95% in 2024, then fell 28.53% in 2025.
  • Iovance Biotherapeutics' Total Non-Current Liabilities stood at $85.4 million in 2023, then fell by 9.07% to $77.7 million in 2024, then decreased by 1.87% to $76.2 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Total Non-Current Liabilities are $76.2 million (Q4 2025), $76.9 million (Q3 2025), and $79.8 million (Q2 2025).